ライフサイエンスコーパス: circulating tumor cell

1 heterogeneity in tumors and analyzing single circulating tumor cells.

2 c monitoring, most notably in the context of circulating tumor cells.

3 d 19%, respectively, had detectable AR-V7 in circulating tumor cells.

4 of prostate cancer from biopsy specimens and circulating tumor cells.

5 arkers, single-nucleotide polymorphisms, and circulating tumor cells.

6 changes in tumor burden, than did CA 15-3 or circulating tumor cells.

7 n of tumors and the colonization of lungs by circulating tumor cells.

8 nversely correlated with stage and amount of circulating tumor cells.

9 ies examine the cytoskeleton of detached and circulating tumor cells.

10 etection of bone marrow micrometastases, and circulating tumor cells.

11 ent manner, resulting in elevated numbers of circulating tumor cells.

12 were measured in blood, hair follicles, and circulating tumor cells.

13 te cancer, by greatly reducing the number of circulating tumor cells.

14 lls), metastatic prostate cancer lesions and circulating tumor cells.

15 lung but powerfully licenses colonization by circulating tumor cells.

16 to be a vital trait of cancer cells such as circulating tumor cells, allowing them to undergo revers

17 Less circulating tumor cells along with reduction in malignan

18 TF on circulating tumor cells also leads to the coating of the

19 d dynamic range for routine detection of PCa circulating tumor cells and can be adapted to detect oth

20 analysis in high cellular backgrounds (e.g., circulating tumor cells and fetal cells in maternal bloo

21 carcinoma cells reduced the number of viable circulating tumor cells and inhibited lung metastasis in

22 ing levels of TGF-beta1 as well as increased circulating tumor cells and lung metastases.

23 reduced tumor size as well as the number of circulating tumor cells and metastases in an orthotopic

24 cer following resection, elevated numbers of circulating tumor cells and more spontaneous metastases.

25 noikis enables them to disseminate as viable circulating tumor cells and seed distant organs.

26 mice inhibited extravasation/colonization of circulating tumor cells and significantly reduced metast

27 l assays of drug-target engagement in living circulating tumor cells and therefore have the potential

28 els, ADCC enhancement was crucial to deplete circulating tumor cells and to suppress metastases.

29 Circulating tumor cells and tumor-derived RNA in the blo

30 rovements in measurable soft tissue disease, circulating tumor cells, and bone biomarkers.

31 algesic use, measurable soft tissue disease, circulating tumor cells, and bone biomarkers.

32 ctive surveillance have evaluated microRNAs, circulating tumor cells, and exosomes.

33 re thus offers a unique route for separating circulating tumor cells, and for label-free cell separat

34 Baseline and early changes in circulating tumor cells appear useful as a prognostic fa

35 for rare cell detection applications (e.g., circulating tumor cells), applications requiring large p

36 herringbone patterns suitable for capture of circulating tumor cells are made as a demonstrative appl

37 Circulating tumor cells are responsible for seeding meta

38 of metastasis, detection and destruction of circulating tumor cells are vital for impeding metastasi

39 The evaluation of circulating tumor cells assists in determining prognosis

40 ing the extravasation process or re-entry of circulating tumor cells at metastatic sites.

41 Cx-43 has been shown to facilitate arrest of circulating tumor cells at the vascular endothelium, mel

42 Circulating tumor cell-based AR-V7 detection may serve a

43 We report that circulating tumor cells become trapped within NETs in vi

44 date by tumor recurrence as a consequence of circulating tumor cells before the surgery.

45 biomarker, expressed on prostate tissue and circulating tumor cells but also found in serum.

46 tinuous high-throughput selective capture of circulating tumor cells by dielectrophoresis at arrays o

47 Kim et al. now discover that circulating tumor cells can reinfiltrate tumors at their

48 Recent scientific advances in understanding circulating tumor cells, cell-free DNA/RNA, and exosomes

49 val outcomes was evaluated and compared with circulating tumor cells (CellSearch).

50 Circulating tumor cell clusters (CTC clusters) are poten

51 Circulating tumor cell clusters (CTC clusters) are prese

52 This result suggests that circulating tumor cell clusters might be able to better

53 Intriguingly, locally disseminated clusters, circulating tumor cell clusters, and lung micrometastase

54 , local dissemination, intravascular emboli, circulating tumor cell clusters, and micrometastases.

55 mutation, which confers drug resistance, in circulating tumor cells collected from patients with EGF

56 Baseline circulating tumor cell concentrations were predictive of

57 During cancer metastasis, circulating tumor cells constantly experience hemodynami

58 Circulating tumor cells continue to provide important pr

59 ine phosphatase level (r = 0.572, P < .001), circulating tumor cell count (r = 0.613, P = .004), and

60 hange in prostate-specific antigen level and circulating tumor cell count (r = 0.63 [95% CI: 0.27, 0.

61 ion with prostate-specific antigen level and circulating tumor cell count were assessed by using Spea

62 ntigen level or a confirmed reduction in the circulating tumor-cell count from 5 or more cells per 7.

63 ored, using individual patient data, week 13 circulating tumor cell (CTC) and prostate-specific antig

64 linical benefit from early taxane switch and circulating tumor cell (CTC) biomarkers to interrogate m

65 technique for improving immunoaffinity-based circulating tumor cell (CTC) capture by patterning regio

66 The circulating tumor cell (CTC) count has been shown as a p

67 ignificance of (18)F-FDG PET/CT findings and circulating tumor cell (CTC) count in patients with bone

68 Conventional circulating tumor cell (CTC) detection strategies rely o

69 We evaluated circulating tumor cell (CTC) enumeration as a surrogate

70 Circulating tumor cell (CTC) enumeration has not been pr

71 SA progression; safety and tolerability; and circulating tumor cell (CTC) enumeration.

72 the primary tumor vascular response and the circulating tumor cell (CTC) fraction derived from a tis

73 th PSA > 4.0 ng/mL, safety and tolerability, circulating tumor cell (CTC) levels, and seven plasma IG

74 ogy Group (ECOG) performance status (PS) and circulating tumor cell (CTC) numbers.

75 om primary tumors are believed to facilitate circulating tumor cell (CTC) seeding of distant metastas

76 irculating cancer stem cells (CCSCs), a rare circulating tumor cell (CTC) type, recently arose as a u

77 Such restrictions limit the translation of circulating tumor cell (CTC)-based liquid biopsy assays

78 Multicellular aggregates of circulating tumor cells (CTC clusters) are potent initia

79 drug resistance-conferring gene mutations on circulating tumor cells (CTC) and cell-free circulating

80 The interaction between circulating tumor cells (CTC) and endothelial cells duri

81 Increases in gammaH2AX response in circulating tumor cells (CTC) and PBMCs were observed in

82 This panel was also applied to circulating tumor cells (CTC) and provided evidence that

83 Most of the current strategies for detecting circulating tumor cells (CTC) are based on the epithelia

84 Circulating tumor cells (CTC) are emerging as a powerful

85 Circulating tumor cells (CTC) are shed in peripheral blo

86 ss the current and future potential of using circulating tumor cells (CTC) as a biomarker to assess s

87 EGFR expression was also observed in circulating tumor cells (CTC) during prostate cancer met

88 gital pathology features on 9,225 individual circulating tumor cells (CTC) from 179 unique metastatic

89 Molecular characterization of circulating tumor cells (CTC) from blood is technically

90 ), a technique previously used for isolating circulating tumor cells (CTC) from blood.

91 erse transcriptase PCR in PCa cell lines and circulating tumor cells (CTC) from CRPC patients.

92 specific marker exists for the detection of circulating tumor cells (CTC) from different types of sa

93 Cancer stem-like cells (CSC) and circulating tumor cells (CTC) have related properties as

94 The detection and characterization of circulating tumor cells (CTC) holds great promise for pe

95 Circulating tumor cells (CTC) in blood are promising new

96 Circulating tumor cells (CTC) in the blood are hypothesi

97 Circulating tumor cells (CTC) in the peripheral blood co

98 The abundance of circulating tumor cells (CTC) indicates patient prognosi

99 Detection of circulating tumor cells (CTC) is advancing as an effecti

100 Analysis of circulating tumor cells (CTC) isolated from the peripher

101 Blood tests to detect circulating tumor cells (CTC) offer great potential to m

102 studies have separately shown the utility of circulating tumor cells (CTC) or cell-free tumor-related

103 Circulating tumor cells (CTC) quantified in cancer patie

104 Circulating tumor cells (CTC) released into blood from p

105 A method is presented for the detection of circulating tumor cells (CTC) using mass spectrometry (M

106 Further, both cCAF and circulating tumor cells (CTC) were significantly greater

107 Here, we evaluated whether circulating tumor cells (CTC) with aberrant ALK-FISH pat

108 mesenchymal transition (EMT) is prominent in circulating tumor cells (CTC), but how it influences met

109 arly detection of metastasis can be aided by circulating tumor cells (CTC), which also show potential

110 temic dissemination is most likely caused by circulating tumor cells (CTC).

111 fective metastatic chemoprevention targeting circulating tumor cells (CTC).

112 al applications, most recently for isolating circulating tumor cells (CTC).

113 tion of tumor cells in the peripheral blood (circulating tumor cells, CTC) and CSF (cerebrospinal flu

114 Circulating tumor cells (CTCs) and [(18)F]fluorodeoxyglu

115 based biopsies (BBBs), blood is purified for circulating tumor cells (CTCs) and clinical utility is t

116 ssess the prognostic and predictive value of circulating tumor cells (CTCs) and disseminated tumor ce

117 Circulating tumor cells (CTCs) and disseminated tumor ce

118 We determined the prevalence of circulating tumor cells (CTCs) and explored their utilit

119 y tumor growth but blocked the production of circulating tumor cells (CTCs) and the formation of lymp

120 Circulating tumor cells (CTCs) are a treasure trove of i

121 Circulating tumor cells (CTCs) are cancer cells released

122 Circulating tumor cells (CTCs) are cancer cells shed fro

123 Circulating tumor cells (CTCs) are established cancer bi

124 Circulating tumor cells (CTCs) are exfoliated at various

125 Circulating tumor cells (CTCs) are important biomarkers

126 Circulating tumor cells (CTCs) are important targets for

127 Circulating tumor cells (CTCs) are of recognized importa

128 Circulating tumor cells (CTCs) are phenotypically hetero

129 Circulating tumor cells (CTCs) are present at low concen

130 Circulating tumor cells (CTCs) are promising biomarkers

131 Circulating tumor cells (CTCs) are rare cancer cells tha

132 Circulating tumor cells (CTCs) are rare cells found in t

133 Circulating tumor cells (CTCs) are shed from a solid tum

134 Circulating tumor cells (CTCs) are shed into the bloodst

135 Here we show that circulating tumor cells (CTCs) can also colonize their t

136 Direct analysis of circulating tumor cells (CTCs) can inform on molecular m

137 Quantitation of circulating tumor cells (CTCs) constitutes an emerging t

138 en receptor splice variant-7 (AR-V7) mRNA in circulating tumor cells (CTCs) correlated with poor outc

139 We tested the hypothesis that circulating tumor cells (CTCs) could predict clinical ou

140 Anticancer drug efficacy has been tested on circulating tumor cells (CTCs) derived from patient bloo

141 Circulating tumor cells (CTCs) detection, enumeration an

142 Circulating tumor cells (CTCs) disseminate from the prim

143 tivator of NF-kappabeta (RANK) in individual circulating tumor cells (CTCs) from 40 late-stage (III-I

144 tion and rapid molecular characterization of circulating tumor cells (CTCs) from a liquid biopsy coul

145 deaths and it is fueled by the generation of circulating tumor cells (CTCs) from a primary tumor depo

146 ole in human cancer, we characterized EMT in circulating tumor cells (CTCs) from breast cancer patien

147 e biomaterial for the capture and release of circulating tumor cells (CTCs) from cancer patient blood

148 thin the circulatory system, platelets guard circulating tumor cells (CTCs) from immune elimination a

149 ndrogen receptor splice variant 7 (AR-V7) in circulating tumor cells (CTCs) from men with castration-

150 t portion of primary breast cancers and also circulating tumor cells (CTCs) from patients with advanc

151 llowed for detection and characterization of circulating tumor cells (CTCs) from patients with cancer

152 enable the detection and isolation of single circulating tumor cells (CTCs) from patients with prosta

153 sitive and high-throughput method to analyze circulating tumor cells (CTCs) from peripheral blood.

154 e examined copy-number aberrations (CNAs) in circulating tumor cells (CTCs) from pretreatment SCLC bl

155 Isolation of circulating tumor cells (CTCs) from the peripheral blood

156 lterations in single primary tumor cells and circulating tumor cells (CTCs) from the same patient.

157 The enumeration of EpCAM-positive circulating tumor cells (CTCs) has allowed estimation of

158 Evaluation of circulating tumor cells (CTCs) has demonstrated clinical

159 Enumeration of circulating tumor cells (CTCs) has proved valuable for e

160 The ability to isolate and analyze rare circulating tumor cells (CTCs) has the potential to furt

161 Circulating tumor cells (CTCs) have a great potential as

162 l as surface marker identification of single circulating tumor cells (CTCs) have been demonstrated.

163 Circulating tumor cells (CTCs) have been detected by us

164 Circulating tumor cells (CTCs) have been linked to cance

165 Although circulating tumor cells (CTCs) have potential as diagnos

166 Serological cell death biomarkers and circulating tumor cells (CTCs) have potential uses as to

167 Circulating tumor cells (CTCs) in blood are associated w

168 quantification and in situ identification of circulating tumor cells (CTCs) in blood are still elusiv

169 sensitive, selective, and rapid detection of circulating tumor cells (CTCs) in blood samples.

170 Presence and frequency of rare circulating tumor cells (CTCs) in bloodstreams of cancer

171 We investigated the relationship of circulating tumor cells (CTCs) in non-small cell lung ca

172 We evaluated the prognostic significance of circulating tumor cells (CTCs) in patients with esophage

173 merase chain reaction (RT-qPCR) detection of circulating tumor cells (CTCs) in patients with melanoma

174 We tested the hypothesis that circulating tumor cells (CTCs) in preoperative periphera

175 The detection of circulating tumor cells (CTCs) in the blood of cancer pa

176 FABP7 as a surrogate biomarker for circulating tumor cells (CTCs) in the blood was assessed

177 elets have been shown to promote survival of circulating tumor cells (CTCs) in the bloodstream by con

178 tage detection and precise quantification of circulating tumor cells (CTCs) in the peripheral blood o

179 R-V7) protein expression and localization on circulating tumor cells (CTCs) is a treatment-specific m

180 The identification and analysis of circulating tumor cells (CTCs) is an important goal for

181 The presence of circulating tumor cells (CTCs) is believed to lead to th

182 he cytoskeletal organization of detached and circulating tumor cells (CTCs) is currently not well def

183 Magnetic capture of circulating tumor cells (CTCs) is one of the most promis

184 port that elevated expression of each GEF in circulating tumor cells (CTCs) isolated from the periphe

185 Circulating tumor cells (CTCs) may have utility as surro

186 e metastases is challenging; hence, sampling circulating tumor cells (CTCs) may reveal drug-resistanc

187 h the bloodstream either as single migratory circulating tumor cells (CTCs) or as multicellular group

188 aimed to evaluate the relationships between circulating tumor cells (CTCs) or plasma cell-free DNA (

189 Five or more circulating tumor cells (CTCs) per 7.5 mL of blood predi

190 The early detection and eradication of circulating tumor cells (CTCs) play an important role in

191 Rare circulating tumor cells (CTCs) present in the bloodstrea

192 Circulating tumor cells (CTCs) provide the capacity for

193 Analysis of circulating tumor cells (CTCs) provides real-time measur

194 Circulating tumor cells (CTCs) represent a surrogate bio

195 Circulating tumor cells (CTCs) shed from primary and met

196 fically isolate exceedingly small numbers of circulating tumor cells (CTCs) through a monoclonal anti

197 l lines, primary prostate cancer tissues and circulating tumor cells (CTCs) to investigate their role

198 Circulating tumor cells (CTCs) were detected in the hepa

199 We assessed circulating tumor cells (CTCs) with epithelial and mesen

200 gression-free survival (rPFS) and effects on circulating tumor cells (CTCs), bone biomarkers, serum p

201 A potential solution is to characterize circulating tumor cells (CTCs), but this requires overco

202 opic ultrasound (EUS) to count portal venous circulating tumor cells (CTCs), compared with paired per

203 t of an efficient technique for detection of circulating tumor cells (CTCs), due to their significanc

204 nd metastatic disease, through the spread of circulating tumor cells (CTCs), is responsible for the m

205 are often easily accessible in the blood as circulating tumor cells (CTCs), making them ideal target

206 Circulating tumor cells (CTCs), which are prevalent in S

207 Additionally, deletion of miR-182 decreased circulating tumor cells (CTCs), while overexpression of

208 analysis of cancer cells in blood-so-called circulating tumor cells (CTCs)-may provide unprecedented

209 for detection, isolation, and enrichment of circulating tumor cells (CTCs)-rare cells that enter the

210 cancer cells is a new approach for detecting circulating tumor cells (CTCs).

211 gement diagnosis could be performed by using circulating tumor cells (CTCs).

212 al separation methods for rare cells such as circulating tumor cells (CTCs).

213 of cancer metastasis, i.e., extravasation of circulating tumor cells (CTCs).

214 ain a deeper understanding of the biology of circulating tumor cells (CTCs).

215 el single cell analysis platforms focused on circulating tumor cells (CTCs).

216 Increased circulating tumor cells (CTCs; five or more CTCs per 7.5

217 Within an elaborate case study of circulating tumor cells derived from prostate cancer pat

218 d has been an effective tool to perform rare Circulating Tumor Cells detection.

219 Clinical data on survival and circulating tumor cell DNA (ctDNA) concentrations were u

220 MT, however, is not required for metastasis: circulating tumor cells exhibit hybrid epithelial-mesenc

221 tions of tissue samples and the detection of circulating tumor cells for point-of-care applications.

222 ould be an effective tool to directly target circulating tumor cells for the prevention of prostate c

223 ied the expected EGFR activating mutation in circulating tumor cells from 11 of 12 patients (92%) and

224 We isolated circulating tumor cells from 27 patients with metastatic

225 cer cell model for brain metastasis based on circulating tumor cells from a breast cancer patient and

226 rous devices developed to isolate individual circulating tumor cells from blood, these devices are in

227 or splice variant 7 messenger RNA (AR-V7) in circulating tumor cells from men with advanced prostate

228 Detection of AR-V7 in circulating tumor cells from patients with castration-re

229 n and on-chip phenotypic characterization of circulating tumor cells from peripheral venous blood in

230 se-chain-reaction assay to evaluate AR-V7 in circulating tumor cells from prospectively enrolled pati

231 We captured highly purified circulating tumor cells from the blood of patients with

232 Molecular analysis of circulating tumor cells from the blood of patients with

233 te early treatment of metastasis by clearing circulating tumor cells from vasculature.

234 hly sensitive microfluidic system to capture circulating tumor cells from whole blood of cancer patie

235 Further dissection of the circulating tumor cell gene signature identified signali

236 CTC transcriptomes, we discovered a unique "circulating tumor cell gene signature" that is distinct

237 Circulating tumor cells have been shown to provide impor

238 rs such as cancer antigen 15-3 (CA 15-3) and circulating tumor cells have been widely studied.

239 Detection of rare cells, such as circulating tumor cells, have many clinical applications

240 Moreover, molecular characterization of circulating tumor cells holds promise for furthering the

241 tudies in which longitudinal biomarkers (eg, circulating tumor cells, immune response to a vaccine, a

242 assay of circulating tumor DNA, CA 15-3, and circulating tumor cells in 30 women with metastatic brea

243 d this coincided with a dramatic decrease in circulating tumor cells in a patient with non-Hodgkin's

244 latory shear stress in cellular responses of circulating tumor cells in a physiologically relevant mo

245 IGF1R also resulted in a decreased number of circulating tumor cells in blood of tumor-bearing mice.

246 In some applications (e.g., working with circulating tumor cells in blood), only a limited number

247 in metastatic capacity and in the number of circulating tumor cells in both the E2F1 and E2F2 knocko

248 label-free identification and measurement of circulating tumor cells in cancer research and disease m

249 ce, respectively, and a striking increase in circulating tumor cells in mice bearing tuberin-null xen

250 y, OGX-427 treatment decreased the number of circulating tumor cells in patients with metastatic cast

251 it of reducing tumor size, PTX increased the circulating tumor cells in the blood and enhanced the me

252 er dormancy is evident from the detection of circulating tumor cells in the blood and tissue-residing

253 Circulating tumor cells in the blood of patients are bot

254 and this was associated with a reduction in circulating tumor cells in the E2F2 knockout.

255 Most recently, the detection of circulating tumor cells in the peripheral blood of patie

256 eveloped for rapid and direct enumeration of circulating tumor cells in the presence of whole blood.

257 novehicle can also effectively eliminate the circulating tumor cells in vivo and inhibit development

258 N formation augmented capillary retention of circulating tumor cells in vivo and rapid re-attachment

259 ADT-sensitivity, and reduces the shedding of circulating tumor cells in vivo with significant shrinka

260 the survival and growth of metastasizing and circulating tumor cells in vivo.

261 specific cells from complex matrices (i.e., circulating tumor cells in whole blood).

262 ging of gastrointestinal tract, bladder, and circulating tumor cells (in vivo flow cytometry); and in

263 cells into the mouse leads to the release of circulating tumor cells into the vasculature, which seed

264 AR-V expression in patient tissues or circulating tumor cells is associated with resistance to

265 A platform for capture and release of circulating tumor cells is demonstrated by utilizing pol

266 Since hematogenous dissemination of circulating tumor cells is the major route of metastasis

267 of fluid-based assays, notably, exosomes and circulating tumor cells (liquid biopsy), as tools for fu

268 le of mechanotransduction in cancer, and how circulating tumor cells may be capable of continuously c

269 isrupt the HA machinery of primary tumor and circulating tumor cells may enhance the effectiveness of

270 Molecular characterization of circulating tumor cells may provide a strategy for nonin

271 We also discuss circulating tumor cells measured with the CellSearch ass

272 In this model, circulating tumor cell numbers are significantly reduced

273 t anti-CD47 antibody-mediated elimination of circulating tumor cells occurred through phagocytosis, a

274 d in the presence of platelets in vitro, and circulating tumor cells of cancer patients display coexp

275 ng predictor of PFS, even in the presence of circulating tumor cells ( P = .004).

276 Circulating tumor cells provide a source of noninvasivel

277 mediated interactions among immune cells and circulating tumor cells remain elusive.

278 stem cells, endothelial progenitor cells, or circulating tumor cells, require efficient, sensitive, a

279 ug assays with patient-derived cells such as circulating tumor cells requires manipulating small samp

280 vestigate small populations of cells such as circulating tumor cells shed from solid tumors and isola

281 Serial analysis of circulating tumor cells showed that a reduction in the n

282 ovides an important new tool for identifying circulating tumor cell subtypes.

283 nvolvement, yet did not affect the levels of circulating tumor cells, suggesting that reduced organ m

284 nd to move collectively, forming clusters of circulating tumor cells that are key tumor-initiating ag

285 promise as an effective means to neutralize circulating tumor cells that enter blood with the potent

286 al utility of the SNARE with prostate cancer circulating tumor cells to demonstrate its ability to pe

287 hrough physical interaction and anchoring of circulating tumor cells to endothelium.

288 ernalization, thus inhibiting the ability of circulating tumor cells to extravasate and colonize, lea

289 The attachment of circulating tumor cells to the blood vessels of distant

290 ells inhibited extravasation/colonization of circulating tumor cells to the lung and inhibited tumor

291 acles that could enhance the reattachment of circulating tumor cells to the vascular endothelium duri

292 It is unknown why only a minority of circulating tumor cells trapped in lung capillaries form

293 FR mutational analysis on DNA recovered from circulating tumor cells using allele-specific polymerase

294 enrichment and molecular characterization of circulating tumor cells using peripheral venous blood in

295 mic alterations were identified; CA 15-3 and circulating tumor cells were detected in 21 of 27 women

296 s of tumor spread were measured serially and circulating tumor cells were detected via fluorescence m

297 CA 15-3 levels and numbers of circulating tumor cells were measured at identical time

298 Furthermore, circulating tumor cells were significantly reduced in tu

299 e metastasis by promoting the association of circulating tumor cells with blood cells to augment tumo

300 f the association of androgen receptor-V7 in circulating tumor cells with resistance to enzalutamide